MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Amgen Inc

Открыт

СекторЗдравоохранение

279.03 -0.31

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

276.26

Макс.

281.57

Ключевые показатели

By Trading Economics

Доход

-2.2B

627M

Продажи

586M

9.1B

P/E

Средняя по отрасли

36.153

57.333

Прибыль на акцию

5.31

Дивидендная доходность

3.43

Рентабельность продаж

6.901

Сотрудники

28,000

EBITDA

-517M

2.9B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+16.62% upside

Дивиденды

By Dow Jones

Дивидендная доходность

Средняя по отрасли

3.43%

2.63%

Следующий отчет о доходах

1 мая 2025 г.

Дата следующей выплаты дивидендов

6 июн. 2025 г.

Следующая эксдивидендная дата

16 мая 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-6B

147B

Предыдущая цена открытия

279.34

Предыдущая цена закрытия

279.03

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

Amgen Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

4 февр. 2025 г., 21:29 UTC

Отчет

Amgen 4Q Sales Up 11% as Ten Products Post Double-Digit Gains

30 окт. 2024 г., 20:18 UTC

Отчет

Amgen Posts Higher 3Q Sales on Strong Demand

10 апр. 2025 г., 05:00 UTC

Отчет

Amgen Is Getting Into the Obesity Drug Business. Buy the Stock Before It Becomes the Next Winner. -- Barrons.com

28 февр. 2025 г., 12:00 UTC

Главные новости

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

4 февр. 2025 г., 21:02 UTC

Отчет

Amgen 4Q SAles Included $1.2 B of Sales From Rare Disease Products >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen 4Q Worldwide Neulasta Sales $98M >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen 4Q Worldwide Enbrel Sales $1.01B >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen 4Q Worldwide Prolia Sales $1.17B >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen Sees FY Rev $34.3B-$35.7B >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen 4Q Adj EPS $5.31 >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen 4Q Worldwide XGEVA Sales $561M >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen Sees FY EPS $10.89-EPS $12.14 >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen Sees FY Adj EPS $20.00-Adj EPS $21.20 >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen 4Q Rev $9.1B >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen 4Q EPS $1.16 >AMGN

4 февр. 2025 г., 21:01 UTC

Отчет

Amgen 4Q Net $627M >AMGN

28 янв. 2025 г., 10:30 UTC

Главные новости

Drug Companies Raise Prices on More Than 800 Drugs in January -- WSJ

27 дек. 2024 г., 07:00 UTC

Отчет

3 Healthcare Stocks to Buy for a 2025 Rebound -- Barrons.com

23 дек. 2024 г., 15:04 UTC

Главные новости

Eli Lilly, Novo Nordisk Stocks Rise. One of These Obesity Drugmakers Just Hit a Landmark. -- Barrons.com

13 дек. 2024 г., 14:53 UTC

Главные новости

Ozempic Works on Kidney Disease, Regulator Says. Why Novo Nordisk Stock Is Falling. -- Barrons.com

30 нояб. 2024 г., 12:00 UTC

Главные новости

Eli Lilly and Novo Nordisk's Obesity Moat Just Got Stronger -- Heard on the Street -- WSJ

26 нояб. 2024 г., 12:34 UTC

Главные новости

Amgen Drug Cut Weight in Closely Watched Study -- WSJ

4 нояб. 2024 г., 12:00 UTC

Главные новости

Big Pharma's Obesity Bonanza Faces New Tests -- Heard on the Street -- WSJ

30 окт. 2024 г., 20:02 UTC

Отчет

Amgen 3Q Sales From Rare Disease Products $1.2B >AMGN

30 окт. 2024 г., 20:02 UTC

Отчет

Amgen CEO: Strong Growth in Sales, Earnings in 3Q Reflects Momentum Being Built Throughout Business>AMGN

30 окт. 2024 г., 20:02 UTC

Отчет

Amgen: 2024 Buybacks Not to Exceed $500M>AMGN

30 окт. 2024 г., 20:02 UTC

Отчет

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

30 окт. 2024 г., 20:02 UTC

Отчет

Amgen 3Q Worldwide Prolia Sales $1.05B >AMGN

30 окт. 2024 г., 20:01 UTC

Отчет

Amgen 3Q Worldwide Enbrel Sales $825M >AMGN

30 окт. 2024 г., 20:01 UTC

Отчет

Amgen 3Q Worldwide XGEVA Sales $541M >AMGN

Сравнение c конкурентами

Изменение цены

Amgen Inc Прогноз

Целевая цена

By TipRanks

16.62% рост

Прогноз на 12 месяцев

Средняя 326.36 USD  16.62%

Максимум 389 USD

Минимум 280 USD

Основано на мнении 18 аналитиков Wall Street, спрогнозировавших целевые цены для Amgen Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

18 ratings

9

Покупка

8

Удержание

1

Продажа

Техническая оценка

By Trading Central

278.68 / 295.18Поддержка и Сопротивление

Краткосрочная

Weak Bearish Evidence

Среднесрочная

Strong Bearish Evidence

Долгосрочная

Bearish Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.